FDA Inspection 1181074 — Eiger BioPharmaceuticals, Inc.
The FDA completed an inspection of Eiger BioPharmaceuticals, Inc. on Sep 29, 2022 in Palo Alto, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 29, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Palo Alto, CA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)